Generic placeholder image

Anti-Infective Agents

Editor-in-Chief

ISSN (Print): 2211-3525
ISSN (Online): 2211-3533

Research Article

Virtual High Throughput Screening to find Suitable Inhibitors for SARSCoV- 2 Main Protease

Author(s): Upasana Phukan, Nakul Neog, Minakshi Puzari, Mohan Sharma, Saurov Mahanta and Pankaj Chetia*

Volume 19, Issue 2, 2021

Published on: 25 September, 2020

Page: [209 - 214] Pages: 6

DOI: 10.2174/2211352518999200925152725

Price: $65

Abstract

Background: COVID-19 caused by SARS-CoV-2 virus which originated in Wuhan and quickly spread across various countries has taken the form of a pandemic. It is now a major health concern worldwide and finding a solution to this problem is of utmost importance. Understanding its origin, transmission, and interaction with different compounds is essential to find probable inhibitors.

Objective: The objective of our study was to search for potential inhibitors of the main protease of SARS-CoV-2 and to assess their drug-like properties.

Methods: In our study, 1909 ligands were filtered through the Lipinski filter and their ADMET properties along with mutagenic nature were analyzed. They were screened for inhibitory activity against the Main Protease of SARS-CoV-2 using BIOVIA Discovery studio.

Results: After virtual high throughput screening, two compounds- apigenin and N-(4-bromophenyl)- 7-hydroxy-2-iminochromene-3-carboxamide were found to have promising binding energies as well as –CDOCKER energy scores compared to the reported inhibitor.

Conclusion: Apigenin seems to be a potential candidate against the main protease of SARS-CoV-2 and must be considered for further experiments.

Keywords: Corona, COVID-19, SARS-CoV-2, protease, virtual high throughput screening, BIOVIA.

Graphical Abstract
[1]
Wu, F.; Zhao, S.; Yu, B.; Chen, Y-M.; Wang, W.; Song, Z.G.; Hu, Y.; Tao, Z.W.; Tian, J.H.; Pei, Y.Y.; Yuan, M.L.; Zhang, Y.L.; Dai, F.H.; Liu, Y.; Wang, Q.M.; Zheng, J.J.; Xu, L.; Holmes, E.C.; Zhang, Y.Z. A new coronavirus associated with human respiratory disease in China. Nature, 2020, 579(7798), 265-269.
[http://dx.doi.org/10.1038/s41586-020-2008-3] [PMID: 32015508]
[2]
Zhou, P.; Yang, X.L.; Wang, X.G.; Hu, B.; Zhang, L.; Zhang, W.; Si, H.R.; Zhu, Y.; Li, B.; Huang, C.L.; Chen, H.D.; Chen, J.; Luo, Y.; Guo, H.; Jiang, R.D.; Liu, M.Q.; Chen, Y.; Shen, X.R.; Wang, X.; Zheng, X.S.; Zhao, K.; Chen, Q.J.; Deng, F.; Liu, L.L.; Yan, B.; Zhan, F.X.; Wang, Y.Y.; Xiao, G.F.; Shi, Z.L. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 2020, 579(7798), 270-273.
[http://dx.doi.org/10.1038/s41586-020-2012-7] [PMID: 32015507]
[3]
Sohrabi, C.; Alsafi, Z.; O’Neill, N.; Khan, M.; Kerwan, A.; Al-Jabir, A.; Iosifidis, C.; Agha, R. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). Int. J. Surg., 2020, 76, 71-76.
[http://dx.doi.org/10.1016/j.ijsu.2020.02.034] [PMID: 32112977]
[4]
Sanders, J.M.; Monogue, M.L.; Jodlowski, T.Z.; Cutrell, J.B. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A review. JAMA, 2020, 323(18), 1824-1836.
[http://dx.doi.org/10.1001/jama.2020.6019] [PMID: 32282022]
[5]
Kampf, G.; Todt, D.; Pfaender, S.; Steinmann, E. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. J. Hosp. Infect., 2020, 104(3), 246-251.
[http://dx.doi.org/10.1016/j.jhin.2020.01.022] [PMID: 32035997]
[6]
Andersen, K.G.; Rambaut, A.; Lipkin, W.I.; Holmes, E.C.; Garry, R.F. The proximal origin of SARS-CoV-2. Nat. Med., 2020, 26(4), 450-452.
[http://dx.doi.org/10.1038/s41591-020-0820-9] [PMID: 32284615]
[7]
Corman, V.M.; Muth, D.; Niemeyer, D.; Drosten, C. Hosts and sources of endemic human coronaviruses. Advances in Virus Research; Kielian, M.; Mettenleiter, T.C.; Roossinck, M.J., Ed(s); Academic Press: Cambridge, 2018, 100, pp. 163-188.
[http://dx.doi.org/10.1016/bs.aivir.2018.01.001]
[8]
Baruah, V.; Bose, S. Immunoinformatics-aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019-nCoV. J. Med. Virol., 2020, 92(5), 495-500.
[http://dx.doi.org/10.1002/jmv.25698] [PMID: 32022276]
[9]
Anand, K.; Palm, G.J.; Mesters, J.R.; Siddell, S.G.; Ziebuhr, J.; Hilgenfeld, R. Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra α-helical domain. EMBO J., 2002, 21(13), 3213-3224.
[http://dx.doi.org/10.1093/emboj/cdf327] [PMID: 12093723]
[10]
Yang, H.; Yang, M.; Ding, Y.; Liu, Y.; Lou, Z.; Zhou, Z.; Sun, L.; Mo, L.; Ye, S.; Pang, H.; Gao, G.F.; Anand, K.; Bartlam, M.; Hilgenfeld, R.; Rao, Z. The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc. Natl. Acad. Sci. USA, 2003, 100(23), 13190-13195.
[http://dx.doi.org/10.1073/pnas.1835675100] [PMID: 14585926]
[11]
Yang, H.; Xie, W.; Xue, X.; Yang, K.; Ma, J.; Liang, W.; Zhao, Q.; Zhou, Z.; Pei, D.; Ziebuhr, J.; Hilgenfeld, R.; Yuen, K.Y.; Wong, L.; Gao, G.; Chen, S.; Chen, Z.; Ma, D.; Bartlam, M.; Rao, Z. Design of wide-spectrum inhibitors targeting coronavirus main proteases. PLoS Biol., 2005, 3(10), e324.
[http://dx.doi.org/10.1371/journal.pbio.0030324] [PMID: 16128623]
[12]
Xue, X.; Yu, H.; Yang, H.; Xue, F.; Wu, Z.; Shen, W.; Li, J.; Zhou, Z.; Ding, Y.; Zhao, Q.; Zhang, X.C.; Liao, M.; Bartlam, M.; Rao, Z. Structures of two coronavirus main proteases: implications for substrate binding and antiviral drug design. J. Virol., 2008, 82(5), 2515-2527.
[http://dx.doi.org/10.1128/JVI.02114-07] [PMID: 18094151]
[13]
Ren, Z.; Yan, L.; Zhang, N.; Guo, Y.; Yang, C.; Lou, Z.; Rao, Z. The newly emerged SARS-like coronavirus HCoV-EMC also has an “Achilles’ heel”: current effective inhibitor targeting a 3C-like protease. Protein Cell, 2013, 4(4), 248-250.
[http://dx.doi.org/10.1007/s13238-013-2841-3] [PMID: 23549610]
[14]
Wang, F.; Chen, C.; Tan, W.; Yang, K.; Yang, H. Structure of Main Protease from Human Coronavirus NL63: Insights for Wide Spectrum Anti-Coronavirus Drug Design. Sci. Rep., 2016, 6, 22677-22677.
[http://dx.doi.org/10.1038/srep22677] [PMID: 26948040]
[15]
Zhou, X.; Wang, F.; Zhou, R.; Song, X.; Xie, M. Apigenin: A Current Review on Its Beneficial Biological Activities. J. Food Biochem., 2017, 41, e12376.
[http://dx.doi.org/10.1111/jfbc.12376]
[16]
Tang, D.; Chen, K.; Huang, L.; Li, J. Pharmacokinetic properties and drug interactions of apigenin, a natural flavone. Expert Opin. Drug Metab. Toxicol., 2017, 13(3), 323-330.
[http://dx.doi.org/10.1080/17425255.2017.1251903] [PMID: 27766890]
[17]
Dong, J.; Qiu, J.; Wang, J.; Li, H.; Dai, X.; Zhang, Y.; Wang, X.; Tan, W.; Niu, X.; Deng, X.; Zhao, S. Apigenin alleviates the symptoms of Staphylococcus aureus pneumonia by inhibiting the production of alpha-hemolysin. FEMS Microbiol. Lett., 2013, 338(2), 124-131.
[http://dx.doi.org/10.1111/1574-6968.12040] [PMID: 23113475]
[18]
Anter, J.; Romero-Jiménez, M.; Fernández-Bedmar, Z.; Villatoro-Pulido, M.; Analla, M.; Alonso-Moraga, A.; Muñoz-Serrano, A. Antigenotoxicity, cytotoxicity, and apoptosis induction by apigenin, bisabolol, and protocatechuic acid. J. Med. Food, 2011, 14(3), 276-283.
[http://dx.doi.org/10.1089/jmf.2010.0139] [PMID: 21182433]
[19]
Hakobyan, A.; Arabyan, E.; Avetisyan, A.; Abroyan, L.; Hakobyan, L.; Zakaryan, H. Apigenin inhibits African swine fever virus infection in vitro. Arch. Virol., 2016, 161(12), 3445-3453.
[http://dx.doi.org/10.1007/s00705-016-3061-y] [PMID: 27638776]
[20]
Khandelwal, N.; Chander, Y.; Kumar, R.; Riyesh, T.; Dedar, R.K.; Kumar, M.; Gulati, B.R.; Sharma, S.; Tripathi, B.N.; Barua, S.; Kumar, N. Antiviral activity of Apigenin against buffalopox: Novel mechanistic insights and drug-resistance considerations. Antiviral Res., 2020, 181, 104870.
[http://dx.doi.org/10.1016/j.antiviral.2020.104870] [PMID: 32707051]
[21]
Zhang, W.; Qiao, H.; Lv, Y.; Wang, J.; Chen, X.; Hou, Y.; Tan, R.; Li, E. Apigenin inhibits enterovirus-71 infection by disrupting viral RNA association with trans-acting factors. PLoS One, 2014, 9(10), e110429.
[http://dx.doi.org/10.1371/journal.pone.0110429] [PMID: 25330384]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy